EBEivind Berge

Eivind Berge

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eivind Berge has a total of 248 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tenecteplase in wake-up ischemic stroke trial: Protocol for a randomized-controlled trial

    by Melinda B Roaldsen, Haakon Lindekleiv, Agnethe Eltoft, Mirza Jusufovic, Mary-Helen Søyland, Jesper Petersson, Bent Indredavik, Arnstein Tveiten, Jukka Putaala, Hanne Christensen, et al.

    Patients with wake-up ischemic stroke who have evidence of salvageable tissue on advanced imaging can benefit from intravenous thrombolysis. It is not known whether patients who do not fulfil such imaging criteria might benefit from treatment, but studies indicate that treatment based on non-contrast CT criteria may be safe. Tenecteplase has shown promising results in patients with acute ischemic stroke. The aim of the Tenecteplase in Wake-up Ischemic Stroke Trial (TWIST) is to compare the effect of thrombolytic treatment with tenecteplase and standard care versus standard care alone in patients with wake-up ischemic stroke selected by non-contrast CT. TWIST is an international, investigator-initiated, multi-centre, prospective, randomized-controlled, open-label, blinded end-point trial of tenecteplase (n = 300) versus standard care (n = 300) in patients who wake up with an acute ischemic stroke and can be treated within 4.5 h upon awakening. Seventy-seven centres in 10 countries (Denmark, Estonia, Finland, Latvia, Lithuania, New Zealand, Norway, Sweden, Switzerland, and the United Kingdom) participate. The primary outcome is the modified Rankin Scale on the ordinal scale (0–6) at three months. TWIST aims to determine the effect and safety of thrombolytic treatment with tenecteplase in patients with wake-up ischemic stroke selected by non-contrast CT. ClinicalTrials.gov NCT03181360. EudraCT Number 2014-000096-80.


  • Value of treatment by comprehensive stroke services for the reduction of critical gaps in acute stroke care in Europe

    by A. J. S. Webb, A. C. Fonseca, E. Berge, G. Randall, F. Fazekas, B. Norrving, E. Nivelle, V. Thijs, G. Vanhooren, for the Stroke Working Group of the European Brain Council Value of Treatment initiative

    Stroke is the second leading cause of death and dependency in Europe and costs the European Union more than €30bn, yet significant gaps in the patient pathway remain and the cost‐effectiveness of comprehensive stroke care to meet these needs is unknown. The European Brain Council Value of Treatment Initiative combined patient representatives, stroke experts, neurological societies and literature review to identify unmet needs in the patient pathway according to Rotterdam methodology. The cost‐effectiveness of comprehensive stroke services was determined by a Markov model, using UK cost data as an exemplar and efficacy data for prevention of death and dependency from published systematic reviews and trials, expressing effectiveness as quality‐adjusted life‐years (QALYs). Model outcomes included total costs, total QALYs, incremental costs, incremental QALYs and the incremental cost‐effectiveness ratio (ICER). Key unmet needs in the stroke patient pathway included inadequate treatment of atrial fibrillation (AF), access to neurorehabilitation and implementation of comprehensive stroke services. In the Markov model, full implementation of comprehensive stroke services was associated with a 9.8% absolute reduction in risk of death of dependency, at an intervention cost of £9566 versus £6640 for standard care, and long‐term care costs of £35 169 per 5.1251 QALYS vs. £32 347.40 per 4.5853 QALYs, resulting in an ICER of £5227.89. Results were robust in one‐way and probabilistic sensitivity analyses. Implementation of comprehensive stroke services is a cost‐effective approach to meet unmet needs in the stroke patient pathway, to improve acute stroke care and support better treatment of AF and access to neurorehabilitation.


  • High-sensitive cardiac Troponin T and exercise stress test for evaluation of angiographically significant coronary disease

    by Joanna Cwikiel, Ingebjørg Seljeflot, Morten W. Fagerland, Kristian Wachtell, Harald Arnesen, Eivind Berge, Arnljot Flaa


  • Blood pressure variability in hypertensive patients with atrial fibrillation in the VALUE trial

    by Maria H. Mehlum, Knut Liestøl, Torgeir B. Wyller, Tsushung A. Hua, Morten Rostrup, Eivind Berge

    Purpose: Blood pressure variability is associated with traditional cardiovascular risk factors, but little is known about the association with atrial fibrillation. We compared blood pressure variability in patients with and without atrial fibrillation using data from the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. Materials and methods: The VALUE trial was a randomised-controlled trial of valsartan versus amlodipine in patients with hypertension and high cardiovascular risk, followed for 4.2 years (mean). For the present analysis we included patients with electrocardiogram at baseline and during follow-up, and ≥3 visits from 6 months onwards. We compared standard deviation (SD) of all blood pressures within each visit averaged across all visits (within-visit variability) and of mean blood pressure at each visit (visit-to-visit variability) in patients with and without atrial fibrillation at baseline. We similarly compared patients who developed non-persistent or persistent atrial fibrillation during follow-up with those who did not, using t-tests, ANOVA and linear regression. Results: Of 15,245 patients in the VALUE trial, 13,827 were eligible for analysis. SD of visit-to-visit systolic blood pressure was not significantly different between patients with and without atrial fibrillation at baseline (mean difference 0.3 mm Hg, p = 0.4), but significantly higher in patients with incident non-persistent or persistent atrial fibrillation during follow-up than in those who never developed atrial fibrillation (differences 1.2 and 1.8 mm Hg, respectively, p-values p-values SD of within-visit systolic blood pressure was not significantly different between patients with and without atrial fibrillation at baseline (p = 0.4) but significantly higher in patients with persistent atrial fibrillation during follow-up (p = 0.04). Conclusion: In patients treated for hypertension, atrial fibrillation was not associated with increased blood pressure variability, but blood pressure variability was higher in those who developed atrial fibrillation during follow-up.


  • Open Access

    Central masked adjudication of stroke diagnosis at trial entry offered no advantage over diagnosis by local clinicians: Secondary analysis and simulation

    by Peter J. Godolphin, Trish Hepburn, Nikola Sprigg, Liz Walker, Eivind Berge, Ronan Collins, John Gommans, George Ntaios, Stuart Pocock, Kameshwar Prasad, et al.


  • Response to letters from Torp-Pedersen and colleagues and de Courson and colleagues

    by Maria H Mehlum, Knut Liestøl, Sverre E Kjeldsen, Eivind Berge

  • Open Access

    P826Increase in cardiac biomarkers during exercise stress test in patients with angiographically verified coronary artery disease

    by J Cwikiel, I Seljeflot, E Berge, K Wachtell, A Flaa

    Background: In stable patients with chest pain or angina equivalent symptoms, exercise stress test has a moderate sensitivity and specificity. Adding a reliable cardiac biomarker to the exercise test could potentially improve the accuracy of the test. We therefore compared the change of NT-proBNP and hs-cTnT during exercise stress test in patients with angiographically verified CAD and in those without CAD. We hypothesized that NT-proBNP and hs-cTnT would increase to a higher extent in CAD patients.


  • Effect of strenuous exercise on mediators of inflammation in patients with coronary artery disease

    by Joanna Cwikiel, Ingebjørg Seljeflot, Eivind Berge, Ida Unhammer Njerve, Hilde Ulsaker, Harald Arnesen, Arnljot Flaa


  • Open Access

    Are there opportunities for a closer collaboration on clinical stroke research in Europe?

    by Eivind Berge, Gary A. Ford, Christian Stapf, Rustam Al-Shahi Salman, Urs Fischer, Sarah Coveney, Christian Weimar, Marcel Arnold, Anita Arsovska, Robin Lemmens, et al.

    Introduction: One of the aims of the European Stroke Organisation (ESO) is to facilitate academic, multinational clinical stroke research. However, despite examples of successful regional and national stroke research networks and collaborative groups, there is no organisational structure at a European level that can facilitate multinational clinical stroke research. Materials and methods: In a project including a survey and a workshop and involving stroke researchers in the ESO, we sought to identify the challenges faced by existing clinical stroke research networks, to define the purpose and roles of any future European stroke research collaboration, and to propose an organisational structure. Results: The survey and workshop gave strong support for an alliance model with independent network members, with the purpose of facilitating clinical stroke research through improved coordination and communication, provision of support, education, and advocacy and communication with other stakeholders. The focus of a proposed European clinical stroke research alliance should be multinational randomised-controlled trials in acute care, prevention and rehabilitation, but the alliance could also support other forms of multi-national clinical stroke research. Conclusion: There is an interest for increased collaboration on multinational clinical stroke research in Europe, in the form of an alliance of independent research networks and collaborative groups. The ESO Trials Network Committee will continue consultation with existing stroke research networks and collaborative groups, and other key stakeholders, to assess the feasibility and support for development of an ESO Trials Alliance.


  • Abstract TMP15: Penumbral Rescue by Normobaric O2 in Ischemic Stroke With Target Mismatch ProFile (PROOF)

    by Sven Poli, Jean-Claude Baron, Robin Lemmens, Patrik Michel, Robert Mikulik, Carlos Molina, Daniel Strbian, Turgut Tatlisumak, Guillaume Turc, Jens Fiehler, et al.

    Introduction/Hypothesis: Despite effective reperfusion therapies, outcome following ischemic stroke (IS) often remains poor. Shortly after IS onset, the already necrotic area is surrounded by the severely hypoperfused but still viable penumbra. Sustaining the latter may widen treatment time windows and improve outcomes. As tissue damage in IS is primarily mediated by hypoxia, increasing penumbral oxygen (O2) supply seems a logical approach. Normobaric hyperoxygenation (NBHO) increased penumbral O2 and attenuated brain injury when initiated early in animal models of transient vessel occlusion. The few clinical trials conducted so far did not adapt these insights: NBHO initiation was late (treatment windows of more than 9 hours) and patients eligible for intravenous thrombolysis and endovascular treatment were excluded. Methods: Multi-center, randomized phase-II proof-of-concept trial studying NBHO adjunct to standard IS treatment; adaptive patient sample size of 180 to 460 depending on interim analysis. Eligibility: Patients with an acute large vessel occlusion in the anterior circulation (terminal ICA plus M1, proximal M1, or distal M1) and an Alberta Stroke Program Early CT Score of 7 or higher. Study treatment must be initiated prior to recanalization therapy and within 3 hours after IS onset. NBHO is achieved by administration of high-flow O2 (40 L/min) via non-rebreather face mask with reservoir or FiO2 of 1.0 during mechanical ventilation. NBHO will be stopped after endovascular treatment or applied for a maximum of four hours in case of not-attempted endovascular treatment. Controls will receive standard O2 supplementation whenever required. Primary Endpoint: Infarct growth from baseline to 24 hours; key secondary endpoint: Δ24h-NIHSS. Conclusion: PROOF is the first clinical trial to incorporate two cornerstones of effective experimental NBHO: early initiation and fast reperfusion. If proven beneficial, phase-III trials may be undertaken. Considering its low cost, NBHO may impact stroke care worldwide.